Frontier Bio (FBIO) Bolstering it’s Warchest.

Fortress Biotech Announces Pricing of Series A Preferred Stock Offering NEW YORK, Nov. 25, 2019 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Common Stock: Nasdaq: FBIO)...
True Nature, Mitesco, Biotech Stock Review

Is True Nature (TNTY) $0.04, Nearing a Breakout?

After a Tough Year, a Series of Development Releases Appears to Have Halted True Natures Downtrend and Move to a Possible Breakout. Only time...
True Nature, Mitesco, Biotech Stock Review

True Nature’s (TNTY) CEO Larry Diamond on Wall Street Analyzer.

Larry Diamond Reveals Some of True Nature's Goals and Ambitions to Incubate Medical Related Startups to Benefit All Shareholders. "Been there, done that -...
biogen, biotech stock review

Biotech’s Turning Up…

Biotech Sector Gains Near 10% in Past Month, After Biogen (BIIB) Reports Breaking News. We keep telling investors (for 40+ years) it's not stock picking...
Dyadic, Biotech Stock Review

Dyadic (DYAI) Highlights.

"In just over a year and a half we have entered into over 15 proof of concept collaborations for both human and animal health...
Mustang Bio, Biotech Stock Review

Mustang Bio (MBIO) Highlights.

"With a strong balance sheet and the continued advancement of our gene therapy and CAR T programs, we are well-positioned to execute on our...

Stand Down IV: Remember This? Alta Vista Cancels IPO. David Wetherell Takes a $2...

We are going through some of our very old 'incubator files' back from when we ran the Incubator Stock Review, a spinoff from the...
Internet Stock Review

What We’re Watching.

“Biotech, Beverages and Bears - Oh My!” — Daniel K. McMahon Headlines this week from winners in the past and just maybe, from some major winners...

Medtech Incubator in Final Stages of Launch.

TrueNature (TNTY) Has Spent the Past Year Gearing Up. News of a Launch and First Incubation Effort Could be Around the Corner and Attract...
Dyadic

Investor Presentation Slides From Dyadic (DYA) $6.40.

Really, How Do We Do It? Live Short Term Chart INVESTOR PRESENTATION LONGER TERM CHART Client, see published reports for disclosure and disclaimer details.

Latest article

Jeffrey Gundlach: Reckoning is Coming.

Jeffrey Edward Gundlach is a businessman, fund manager, and philanthropist. He is the founder of DoubleLine Capital, an investment firm. On 11 November 2020, Gundlach remarked in an interview with...

Who’s the Next Eric Sprott?

To say Eric Sprott has left a legendary mark on the world of mining investment would be an understatement. With a career spanning five...

Perpetua (PPTA) Raises $300 Million.

Not a bad day in Idaho. $300 million banked! We look at the dip as a buying opportunity, as does John Paulson & Co.,...